- 4301. Alstrom syndrome
- [ ] (UMLS (CSP) C0268425) =Congenital Abnormality; Disease or Syndrome
| - 4351. Altretamine/Cyclophosphamide/Methotrexate
- (UMLS (NCI) C0279409) =Therapeutic or Preventive Procedure
|
- 4302. ALT
- [Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI) ( NCI )] (UMLS (NCI) C0376147) =Amino Acid, Peptide, or Protein; Enzyme
| - 4352. Altretamine/Doxorubicin/Fluorouracil/Mitomycin
- (UMLS (NCI) C0279486) =Therapeutic or Preventive Procedure
|
- 4303. ALT ESOTROP W X/Y PATTRN
- [ ] (UMLS (ICD9CM) C0155327) =Disease or Syndrome
| - 4353. Altretamine/Doxorubicin/Fluoxymesterone/Methotrexate/Mitolactol/Prednisone/Tamoxifen/Vincristine
- (UMLS (NCI) C0280614) =Therapeutic or Preventive Procedure
|
- 4304. ALT ESOTROPIA W A PATTRN
- [ ] (UMLS (ICD9CM) C0155325) =Disease or Syndrome
| - 4354. Altretamine/Doxorubicin/Melphalan
- (UMLS (NCI) C0279477) =Therapeutic or Preventive Procedure
|
- 4305. ALT ESOTROPIA W V PATTRN
- [ ] (UMLS (ICD9CM) C0155326) =Disease or Syndrome
| - 4355. Altretamine/Doxorubicin/Methotrexate
- (UMLS (NCI) C0279479) =Therapeutic or Preventive Procedure
|
- 4306. ALT EXOTROP W X/Y PATTRN
- [ ] (UMLS (ICD9CM) C0155333) =Disease or Syndrome
| - 4356. Altretamine/Etoposide
- (UMLS (NCI) C0281629) =Therapeutic or Preventive Procedure
|
- 4307. ALT EXOTROPIA W A PATTRN
- [ ] (UMLS (ICD9CM) C0155331) =Disease or Syndrome
| - 4357. Altretamine/Etoposide/Methotrexate
- (UMLS (NCI) C0280599) =Therapeutic or Preventive Procedure
|
- 4308. ALT EXOTROPIA W V PATTRN
- [ ] (UMLS (ICD9CM) C0155332) =Disease or Syndrome
| - 4358. Altretamine/Etoposide/Procarbazine
- (UMLS (NCI) C0279464) =Therapeutic or Preventive Procedure
|
- 4309. Altace
- (UMLS (NCI) C0878061) =Organic Chemical; Pharmacologic Substance
| - 4359. Altretamine/Lomustine/Methotrexate
- (UMLS (NCI) C0279430) =Therapeutic or Preventive Procedure
|
- 4310. Alteration In Cognition
- [Pertaining to or characterized by cognition. That operation of the mind which we become aware of objects of thought or perception; it includes all aspects of perceiving, thinking, or remembering. ( NCI )] (UMLS (NCI) C1392786) Alteration Of Cognitive Function;
Changes, cognitive;
Cognitive Alteration;
Cognitive Change;
Cognitive Changes =Mental or Behavioral Dysfunction ;
| - 4360. Altretamine/Mitomycin/Vinblastine
- (UMLS (NCI) C0291012) =Therapeutic or Preventive Procedure
|
- 4311. Alteration in Respiration
- (UMLS (NCI) C0184551) =Finding ;
| - 4361. Altretamine/Paclitaxel
- (UMLS (NCI) C0281302) =Therapeutic or Preventive Procedure ;
|
- 4312. Alteration of consciousness
- [ ] (UMLS (ICD9CM) C0234428) =Sign or Symptom
| - 4362. altruism
- [consideration and concern for others, as opposed to self-love or egoism, which can be a motivating influence. ( CSP )] (UMLS (CSP) C0002357) =Social Behavior
|
- 4313. ALTERATION OF SENSATIONS
- (UMLS (ICD9CM) C1135206) Alterations of sensations =Disease or Syndrome
| - 4363. Alturas Indian Rancheria, California
- (UMLS (HL7) C1554224) =Population Group =NativeEntityContiguous;
|
- 4314. Alterations in Hearing
- (UMLS (NCI) C0429199) =Finding
| - 4364. Alum adjuvant/gp100 antigen/Interleukin-12/MART-1 antigen/Montanide ISA-51/tyrosinase peptide
- (UMLS (NCI) C1134584) =Therapeutic or Preventive Procedure ;
|
- 4315. Alterations in Smell or Taste
- (UMLS (NCI) C1332239) =Sign or Symptom ;
| - 4365. Alum Adjuvant/Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine
- (UMLS (NCI) C1134502) =Therapeutic or Preventive Procedure
|
- 4316. ALTERED MENTAL STATUS
- (UMLS (ICD9CM) C0278061) =Mental or Behavioral Dysfunction
| - 4366. Alum adjuvant/Monoclonal antibody 4B5 anti-idiotype vaccine
- (UMLS (NCI) C0879387) =Therapeutic or Preventive Procedure
|
- 4317. Alternaria
- [A mitosporic Loculoascomycetes fungal genus including several plant pathogens and at least one species which produces a highly phytotoxic antibiotic. Its teleomorph is Lewia. ( MSH )] (UMLS (CSP) C0002343) =Fungus
| - 4367. ALUMINUM ACETATE
- [A topical astringent that is used as an antiseptic agent. Aluminum acetate is used to treat inflammation, itching, and stinging of the infected skin and promotes healing. ( NCI )] (UMLS (NCI) C0051510) =Organic Chemical; Pharmacologic Substance ;
=acetate;
Inactive Ingredient Preparations =ALUMINUM ACETATE SOLN;
ALUMINUM ACETATE POWDER (GM);
ALUMINUM ACETATE/BENZETHONIUM CL PWDR,TOP;
ALUMINUM ACETATE/ZINC OXIDE PASTE,TOP;
ALUMINUM ACETATE 325 MG;
CARMEX OINT,TOP;
ALUMINUM ACETATE 10.79 %;
ALUMINUM ACETATE 10 %;
|
- 4318. alternate
- [Designates substitute versions for the document in which the link occurs. When used together with the lang attribute, it implies a translated version of the document. When used together with the media attribute, it implies a version designed for a different medium (or media). ( HL7V3.0 )] (UMLS (HL7) C1552848) =Idea or Concept =HtmlLinkType;
| - 4368. aluminum oxide
- [compound, occurring naturally as corundum and in hydrated form as bauxite, that is the raw material in aluminum production. ( CSP )] (UMLS (CSP) C0002374) =Biomedical or Dental Material; Indicator, Reagent, or Diagnostic Aid; Inorganic Chemical
|
- 4319. Alternate character set handling scheme
- (UMLS (HL7) C1547750) =Idea or Concept =HL7 Vocabulary Version 2.5;
=This is the default, indicating that there is no character set switching occurring in this message.;
"The character set switching mode specified in HL7 2.5, section 2.7.2, _Escape sequences supporting multiple character sets_ and section 2.A.46, ""XPN _ extended person name""."
;"This standard is titled ""Information Technology - Character Code Structure and Extension Technique"". ." | - 4369. Aluminum Stearate
- [The aluminum salt of the fatty acid, stearic acid. ( NCI )] (UMLS (NCI) C0102850) =Lipid; Biomedical or Dental Material
|
- 4320. Alternate character sets
- (UMLS (HL7) C1547621) =Intellectual Product =HL7 Vocabulary Version 2.5;
=The printable characters from the ISO 8859/1 Character set;
The printable characters from the ISO 8859/2 Character set;
The printable characters from the ISO 8859/3 Character set;
The printable characters from the ISO 8859/4 Character set;
The printable characters from the ISO 8859/5 Character set;
The printable characters from the ISO 8859/6 Character set;
The printable characters from the ISO 8859/7 Character set;
The printable characters from the ISO 8859/8 Character set;
The printable characters from the ISO 8859/9 Character set;
The printable 7-bit ASCII character set.;
Code for Taiwanese Character Set (BIG-5);
Code for Taiwanese Character Set (CNS 11643-1992);
Code for Chinese Character Set (GB 18030-2000);
Code for Information Exchange (one byte)(JIS X 0201-1976).;
Code of the supplementary Japanese Graphic Character set for information interchange (JIS X 0212-1990).;
Code for the Japanese Graphic Character set for information interchange (JIS X 0208-1990),;
Code for Korean Character Set (KS X 1001);
The world wide character standard from ISO/IEC 10646-1-1993;
UCS Transformation Format, 16-bit form;
UCS Transformation Format, 32-bit form;
UCS Transformation Format, 8-bit form | - 4370. Alupent
- (UMLS (NCI) C0591074) =Organic Chemical; Pharmacologic Substance
|
- 4321. alternate electronic
- [Payment initiated by the payor as the result of adjudicating a submitted invoice that arrived to the payor from an electronic source that did not provide a conformant set of HL7 messages (e.g. web claim submission). ( HL7V3.0 )] (UMLS (HL7) C1555704) =Intellectual Product =ActInvoiceAdjudicationPaymentGroupCode;
| - 4371. Alutiiq
- (UMLS (HL7) C1556071) =Language =SirenikskiYupik;
|
- 4322. Alternate Splicing
- [Alternate Splicing is a process in which multiple protein isoforms or products are generated from a single gene as a result of splicing together different nonconsecutive exons during the processing of initially identical nascent transcripts of a gene into mature mRNA transcripts. An exon may be connected to any one of several alternative exons to form the mRNA and generate related proteins, often in a tissue or developmental stage specific manner. ( NCI )] (UMLS (NCI) C0002345) =Genetic Function
| - 4372. ALV
- [species in the genus Alpharetrovirus, producing latent or manifest lymphoid leukosis in fowl. ( CSP )] (UMLS (CSP) C0004422) =Virus ;
|
- 4323. ALTERNATING ESOTROPIA
- (UMLS (ICD9CM) C0152205) =Disease or Syndrome ;
| - 4373. ALVAC
- [A vaccine based upon the ALVAC Canarypox virus vector. ( NCI )] (UMLS (NCI) C0211671) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance; Immunologic Factor
|
- 4324. ALTERNATING EXOTROPIA
- [ ] (UMLS (ICD9CM) C0152207) =Disease or Syndrome ;
| - 4374. ALVAC CEA B7.1 Vaccine
- [A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells. ( NCI )] (UMLS (NCI) C1134540) ALVAC-CEA B7.1 Vaccine =Pharmacologic Substance; Immunologic Factor ;
|
- 4325. ALTERNATING HYPERPHORIA
- [ ] (UMLS (ICD9CM) C0152220) =Disease or Syndrome ;
| - 4375. ALVAC hB7.1/IFN-G
- (UMLS (NCI) C0677795) =Therapeutic or Preventive Procedure
|
- 4326. alternative complement pathway
- [complement activation sequence initiated by the activation of complement factor C3, which is triggered by the interaction of microbial polysaccharides and properdin without participation of an antigen-antibody reaction. ( CSP )] (UMLS (CSP) C0009546) =Molecular Function ;
=Complement Pathway;
| - 4376. ALVAC-CEA
- [A cancer vaccine containing a canary pox virus (ALVAC) combined with the human carcinoembryonic antigen (CEA) gene. ( NCI )] (UMLS (NCI) C0338246) =Pharmacologic Substance; Biologically Active Substance ;
|
- 4327. Alternative explanations for the event available
- (UMLS (HL7) C1546997) =Idea or Concept =Causality Observations;
| - 4377. ALVAC-CEA Vaccine/Sargramostim
- (UMLS (NCI) C0677999) =Therapeutic or Preventive Procedure
|
- 4328. Alternative Level of Care
- [Provision of Alternate Level of Care to a patient in an acute bed. Patient is waiting for placement in a long-term care facility and is unable to return home. ( HL7V3.0 )] (UMLS (HL7) C1555460) =Intellectual Product =ActMedicalServiceCode;
| - 4378. ALVAC-CEA-B7.1 vaccine/Fluorouracil/Irinotecan/Leucovorin calcium
- (UMLS (NCI) C1134541) =Therapeutic or Preventive Procedure
|
- 4329. Alternative Macrophage Activation-Associated CC Chemokine 1
- [Induced by glucocorticoids, PMA, IL-4, IL-13, and IL-10 and expressed by human CCL18 Gene (Intercrine Beta Family) in lung, lymph nodes, placenta, bone marrow, dendritic cells, and macrophages, secreted 89-aa 10-kDa (precursor) Small Inducible Cytokine A18, an immunoregulatory chemotactic cytokine for naive T cells, CD4+ and CD8+ T cells, and nonactivated lymphocytes involved in inflammatory processes s well as humoral and cell-mediated immunity. CCL18 may be involved in B cell migration into lymph node follicles. (NCI) ( NCI )] (UMLS (NCI) C0541270) =Amino Acid, Peptide, or Protein; Immunologic Factor
| - 4379. ALVAC-CEA-B7.1 vaccine/Fluorouracil/Irinotecan/Leucovorin calcium/Tetanus toxoid
- (UMLS (NCI) C1134542) =Therapeutic or Preventive Procedure
|
- 4330. alternative medicine
- [diagnostic or therapeutic technique which is presently outside the field of conventional medical practice; for use as a 'tag' term index at 'T' emphasis level. ( CSP )] (UMLS (CSP) C0002346) =Biomedical Occupation or Discipline
| - 4380. ALVAC-CEA-B7.1 Vaccine/Tetanus Toxoid
- (UMLS (NCI) C1327928) =Therapeutic or Preventive Procedure; ;
|
- 4331. alternatives to animals in research
- [methods which refine, reduce, or replace the use of animals in research; includes those projects which replace one animal species with a phylogenetically lower species. ( CSP )] (UMLS (CSP) C0003059) =Research Activity ;
| - 4381. ALVAC-hB7.1
- [A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. (NCI04) ( NCI )] (UMLS (NCI) C0796294) =Pharmacologic Substance; Immunologic Factor
|
- 4332. Althose
- (UMLS (NCI) C0699059) =Organic Chemical; Pharmacologic Substance
| - 4382. ALVAC-hB7.1/Canarypox-hIL-12 Melanoma Vaccine
- (UMLS (NCI) C0796341) =Therapeutic or Preventive Procedure
|
- 4333. altitude
- [height above sea level or above the earth's surface. ( CSP )] (UMLS (CSP) C0002349) =Quantitative Concept
| - 4383. ALVAC-hIL-12
- [A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis. (NCI04) ( NCI )] (UMLS (NCI) C0677735) =Pharmacologic Substance; Immunologic Factor
|
- 4334. altitude sickness
- [A morbid condition of ANOXIA caused by the reduced available oxygen at high altitudes. ( MSH )] (UMLS (CSP) C0002351) =Disease or Syndrome
| - 4384. ALVEOL PNEUMONOPATHY NEC
- (UMLS (ICD9CM) C0155913) =Disease or Syndrome ;
|
- 4335. Altretamine/Carboplatin/Cyclophosphamide
- (UMLS (NCI) C0280871) =Therapeutic or Preventive Procedure ;
| - 4385. ALVEOL PNEUMONOPATHY NOS
- (UMLS (ICD9CM) C0155914) =Disease or Syndrome ;
|
- 4336. Altretamine/Carboplatin/Cyclophosphamide/Doxorubicin
- (UMLS (NCI) C0279977) =Therapeutic or Preventive Procedure
| - 4386. Alveolar border of body of mandible closed fracture
- [ ] (UMLS (ICD9CM) C0159331) =Injury or Poisoning
|
- 4337. Altretamine/Carmustine/Mitomycin
- (UMLS (NCI) C0279189) =Therapeutic or Preventive Procedure
| - 4387. Alveolar border of body of mandible open fracture
- [ ] (UMLS (ICD9CM) C0159342) =Injury or Poisoning
|
- 4338. Altretamine/Cisplatin
- (UMLS (NCI) C0279483) =Therapeutic or Preventive Procedure
| - 4388. Alveolar Cell Type I
- [A flattened cell of the alveolar epithelium, distinguished by their greatly attenuated cytoplasm and paucity of organelles. ( NCI )] (UMLS (NCI) C0225699) =Cell
|
- 4339. Altretamine/Cisplatin/Cyclophosphamide
- (UMLS (NCI) C0280604) =Therapeutic or Preventive Procedure
| - 4389. Alveolar Cell Type II
- [A pleomorphic cell of the pulmonary alveolar epithelium that secretes surfactant and is distinguished by abundant cytoplasm containing numerous lipid-rich multilamellar bodies. ( NCI )] (UMLS (NCI) C0225700) =Cell
|
- 4340. Altretamine/Cisplatin/Cyclophosphamide/Doxorubicin
- (UMLS (NCI) C0056451) =Therapeutic or Preventive Procedure
| - 4390. Alveolar Childhood Rhabdomyosarcoma
- [An aggressive malignant mesenchymal neoplasm occurring in children. It is characterized by the presence of round cells with myoblastic differentiation, and a fibrovascular stroma resembling an alveolar growth pattern. ( NCI )] (UMLS (NCI) C0279613) =Neoplastic Process
|
- 4341. Altretamine/Cisplatin/Cyclophosphamide/Fluorouracil
- (UMLS (NCI) C0279427) =Therapeutic or Preventive Procedure
| - 4391. Alveolar Duct
- [The respiratory passage distal to the respiratory bronchiole. Alveolar sacs and alveoli arise from the alveolar duct. ( NCI )] (UMLS (NCI) C0391892) =Body Part, Organ, or Organ Component ;
|
- 4342. Altretamine/Cisplatin/Cyclophosphamide/Misonidazole
- (UMLS (NCI) C0279336) =Therapeutic or Preventive Procedure
| - 4392. alveolar epithelium
- [Epithelia of lung alveoli. The layer of cells covering the lining of the tiny air sacs at the end of the bronchioles. ( NCI )] (UMLS (CSP) C0225694) =Tissue
|
- 4343. Altretamine/Cisplatin/Doxorubicin
- (UMLS (NCI) C0062074) =Therapeutic or Preventive Procedure ;
| - 4393. alveolar macrophage
- [round, granular, mononuclear phagocytes found in the alveoli of the lungs that ingest small inhaled particles resulting in degradation and presentation of the antigen to immunocompetent cells. ( CSP )] (UMLS (CSP) C0085236) =Cell =Histiocyte;
Body System, Pulmonary |
- 4344. Altretamine/Cisplatin/Etoposide
- (UMLS (NCI) C0281013) =Therapeutic or Preventive Procedure
| - 4394. ALVEOLAR MANDB HYPOPLSIA
- [ ] (UMLS (ICD9CM) C0375350) =Anatomical Abnormality ;
|
- 4345. Altretamine/Cisplatin/Etoposide/Mitomycin
- (UMLS (NCI) C0065958) =Therapeutic or Preventive Procedure
| - 4395. ALVEOLAR MANDIB HYPRPLAS
- [ ] (UMLS (ICD9CM) C0375348) =Anatomical Abnormality ;
|
- 4346. Altretamine/Cyclophosphamide/Doxorubicin
- (UMLS (NCI) C0279470) =Therapeutic or Preventive Procedure
| - 4396. ALVEOLAR MAXIL HYPOPLSIA
- [ ] (UMLS (ICD9CM) C0375349) =Anatomical Abnormality ;
|
- 4347. Altretamine/Cyclophosphamide/Doxorubicin/Fluorouracil/Fluoxymesterone/Methotrexate/Prednisone/Tamoxifen/Vinblastine
- (UMLS (NCI) C0280615) =Therapeutic or Preventive Procedure
| - 4397. ALVEOLAR MAXIL HYPRPLSIA
- [ ] (UMLS (ICD9CM) C0375347) =Anatomical Abnormality ;
|
- 4348. Altretamine/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine
- (UMLS (NCI) C0279335) =Therapeutic or Preventive Procedure
| - 4398. Alveolar Pattern
- (UMLS (NCI) C1332240) =Finding ;
|
- 4349. Altretamine/Cyclophosphamide/Doxorubicin/Vincristine
- (UMLS (NCI) C0279183) =Therapeutic or Preventive Procedure
| - 4399. Alveolar Rhabdomyosarcoma
- [A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities. ( NCI )] (UMLS (NCI) C0206655) =Neoplastic Process =rhabdomyoblastoma;
|
- 4350. Altretamine/Cyclophosphamide/Fluorouracil/Methotrexate
- (UMLS (NCI) C0062594) =Therapeutic or Preventive Procedure
| - 4400. Alveolar Rhabdomyosarcoma of Orbit
- [A malignant mesenchymal neoplasm that arises in the orbit. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma. ( NCI )] (UMLS (NCI) C1335126) Alveolar Rhabdomyosarcoma of the Orbit;
Orbit Alveolar Rhabdomyosarcoma;
=Neoplastic Process ;
|
home 
Armenian-English 
top